Blocklisting of Shares

RNS Number : 5666I

Hikma Pharmaceuticals Plc

15 March 2010

 



Block Listing of Shares

Hikma Pharmaceuticals PLC

LONDON, 15 March 2010 - The Board of Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ: HIK), announces that it has made a block listing application to the Financial Services Authority and the London Stock Exchange plc for a total of 700,000 ordinary shares of 10p each in the capital of the Company to be admitted to the Official List of the UK Listing Authority.  It is expected that admission will be granted on 16 March 2010 and trading will commence on 17 March 2010. 

The shares, when issued, will be issued fully paid and rank pari passu in all respects with the existing issued ordinary shares of the Company.  The shares will be issued pursuant to the vesting of shares under the Hikma Pharmaceuticals PLC 2005 Long Term Incentive Plan (the "Plan"). Participants in the Plan have or will become entitled to these shares following the vesting of the shares.

For further information, please contact:

Henry Knowles, Company Secretary                   
Hikma Pharmaceuticals PLC                                                                              [phone]

Susan Ringdal, Investor Relations Director                      

Hikma Pharmaceuticals PLC                                                                              [phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics".  Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe.  In 2008, the Group achieved revenues of $580.7 million (2007 $449 million) and profit attributable to shareholders was $57.1 million (2007 $63 million).  For news and other information, please visit www.hikma.com.

 

END

 

 

BLRKKPDQCBKKBND